E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Postoperative wound infection following implant removal below the knee |
Postoperatieve wondinfectie na verwijderen van osteosynthesemateriaal onder de knie |
|
E.1.1.1 | Medical condition in easily understood language |
Postoperative wound infection |
Postoperatieve wondinfectie na verwijderen van lichaamsvreemd materiaal |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Microbiological Phenomena [G06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
the objective is to study the (cost-)effectiveness of a single intravenous gift of antibiotic
prophylaxis with a first generation cephalosporin prior to implant removal following surgical fixation of foot, ankle and/or lower leg fractures |
Doel is om het effect van een eenmalige preoperatieve profylactische gift antibiotica op het voorkomen van een POWI na VOSM te beoordelen |
|
E.2.2 | Secondary objectives of the trial |
Health-related quality of life, functional outcome, health care utilization, including transmural care, and costs from a health care and societal perspective (secondary outcomes). |
Secundaire uitkomstmaten zijn kwaliteit van leven, functionele uitkomst en kosteneffectiviteit/besparing. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Consecutive patients of all ethnic backgrounds, aged 18 to 75 years, scheduled for implant removal
following foot, ankle and/or lower leg fracture surgery are included after written informed consent. |
Patienten 18-75 jaar waarbij osteosynthesemateriaal onder de knie verwijderd wordt, van alle etnische achtergronden met informed consent. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria are: removal and re-implanting of osteosynthetic material in the same session; an active wound infection or (plate) fistula; antibiotic treatment at time of elective implant removal for a concomitant disease or infection; a medical history of an allergic reaction to a cephalosporin; insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate. |
opnieuw plaatsen OSM in zelfde sessie, actieve wondinfectie of fistel, antibiotische behandeling, allergie voor cefalosporine, onvoldoende beheersing van de Nederlandse taal om de formulieren te kunnen invullen. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
A POWI within 30 days after implant removal as defined by the criteria applied by the CDC and diagnosed by the attending physician. |
Een POWI binnen 30 dagen gedefinieerd volgens de criteria van de CDC en gediagnosticeerd door een arts |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
30 days postoperatively |
30 dagen postoperatief |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes include:
-health-related quality of life as measured by the EQ-5D questionnaire.
-difference in functional outcome as assessed with the Lower Extremity Functional Scale (LEFS).
-patient satisfaction as measured by a ten-point Visual Analog Scale.
-health care resources utilization (including amongst others, number of visits to the general practitioner and use of home care organizations) as measured by way of a combination of patient questionnaires
-costs (economic evaluation including budget impact analysis) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
0 days, 1 month, 6 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Natriumchloride 0.9% |
Sodiumchloride 0.9% |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Laatste bezoek van laatste patient (dus 6 maanden na laatste inclusie) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |